ライフサイエンスコーパス: endothelin

1 (LPA; acting through the LPA1 receptor) and endothelin.

2 othelial cells by vasoactive signals such as endothelins.

3 orsal Jag1 expression but also by inhibiting endothelin 1 (Edn1) expression in the pharyngeal endoder

4 perturbations demonstrates complex roles for Endothelin 1 (Edn1) signaling in the intermediate joint-

5 emonstrate rs9349379 regulates expression of endothelin 1 (EDN1), a gene located 600 kb upstream of P

6 etermine the selective affinity of EDNRA for endothelin 1 (EDN1), its major physiological ligand, and

7 ular density) and the potent vasoconstrictor endothelin 1 (EDN1); we assayed the activity of angioten

8 Endothelin 1 (ET-1) evokes histamine-independent pruritu

9 des, of which 3 distinct isoforms exist, and endothelin 1 (ET-1) is the most abundant and the best-ch

10 Endothelin 1 (ET-1), mainly produced from vascular endot

11 mpaired vasodilator reactivity and increased endothelin 1 (ET-1)-mediated vasoconstriction, two abnor

12 th the concentration of the vasoconstrictor, endothelin 1 (P = 0.0005), and negatively with the conce

13 eased expression of vasoconstrictor molecule endothelin 1 and a concomitant decrease in vasodilatory

14 We propose that downregulation of endothelin 1 and upregulation of vascular endothelial gr

15 ycoprotein to proteolipid protein 1 and both endothelin 1 and vascular endothelial growth factor.

16 heart, vascular remodeling, and raised serum endothelin 1 levels.

17 e C signaling, glutamate receptor signaling, endothelin 1 signaling, and cardiac hypertrophy signalin

18 ects, but not in vascular dementia, in which endothelin 1 tended to be elevated, perhaps reflecting a

19 r analysis of the Bristol cohort showed that endothelin 1 was reduced in the white matter in Alzheime

20 amma inducible protein 10 (IP10; CXCL10) and endothelin 1 were raised and strongly correlated togethe

21 e complement anaphylatoxins C3a and C5a, and endothelin 1, induced human MCs rapidly to secrete small

22 atory BP), arterial stiffness, nitric oxide, endothelin 1, or blood lipid profile.

23 resence of an endothelin-converting enzyme 1/endothelin 1-SphK positive feedback loop.

24 er quartile); pulmonary hypertension and low endothelin-1 <1.7 pg/mL; lower 3 quartiles); no pulmonar

25 ould be explained by an enhanced response to endothelin-1 (20% greater reduction in lumen diameter, P

26 ls of the endothelium-derived C-terminal-pro-endothelin-1 (both p < 0.02).

27 d cardiovascular progenitors using WNT3A and endothelin-1 (EDN1) human recombinant proteins.

28 nduced glomerulosclerosis is associated with endothelin-1 (EDN1) release by podocytes, which mediates

29 (Ednra) expression and increased circulating endothelin-1 (Edn1).

30 newborn arteries also expresses and releases endothelin-1 (ET-1) and initiates endothelium-dependent

31 s, correlate with increased plasma levels of endothelin-1 (ET-1) and other functional markers of PH i

32 creased levels of the potent vasoconstrictor endothelin-1 (ET-1) and PHT.

33 Endothelin-1 (ET-1) antagonists are a possibility becaus

34 Gene profiling identified inter alia endothelin-1 (ET-1) as one of the target genes of P2Y4 i

35 Hepatic production and release of endothelin-1 (ET-1) binding to endothelin B (ETB) recept

36 Previous studies suggest that endothelin-1 (ET-1) contributes to the pathogenesis of E

37 Endothelin-1 (ET-1) dose and time-dependently up-regulat

38 ivation of endothelin-A receptor (ET(A)R) by endothelin-1 (ET-1) drives epithelial-to-mesenchymal tra

39 (NGAL), kidney injury molecule-1 (KIM-1) and endothelin-1 (ET-1) during EVKP in a series of discarded

40 Endothelial expression and the release of endothelin-1 (ET-1) in levels sufficient to initiate vas

41 Endothelin-1 (ET-1) induces matrix-associated gene expre

42 Endothelin-1 (ET-1) is a potent endothelial-derived vaso

43 The vasoconstrictor peptide endothelin-1 (ET-1) is a transcriptional target of TGF-b

44 Since endothelin-1 (ET-1) is implicated in blood pressure (BP)

45 termine whether vascular endothelial-derived endothelin-1 (ET-1) is important for skin Na(+) bufferin

46 ceptor mediating the vasodilatory effects of endothelin-1 (ET-1) is induced by OA-NO2 Inasmuch as ET-

47 tic brain injury or subarachnoid hemorrhage, endothelin-1 (ET-1) is induced resulting in cerebral vas

48 Endothelin-1 (ET-1) is involved in the pathogenesis of c

49 estigated whether the potent vasoconstrictor endothelin-1 (ET-1) is involved.

50 Endothelin-1 (ET-1) is unique among a broad range of hyp

51 Increased endothelin-1 (ET-1) levels, disordered thiol protein sta

52 rum concentrations of the vasoactive protein endothelin-1 (ET-1) occur in the setting of systemic inf

53 The present study investigated the effect of endothelin-1 (ET-1) on cholinergic mechanisms of end-org

54 n endogenous inhibitor of NO production, and endothelin-1 (ET-1) oppose the actions of NO, suggesting

55 Endothelin-1 (ET-1) promotes renal damage during cardiov

56 edominantly responsible for producing active endothelin-1 (ET-1), a mitogenic peptide implicated in t

57 ) correlated with increased plasma levels of endothelin-1 (ET-1), a potent vasoconstrictor, in sickle

58 Vasoconstrictors, including endothelin-1 (ET-1), inhibit myocyte BK channels, leadin

59 ed an endogenous inhibitor of remyelination, Endothelin-1 (ET-1), which is highly expressed in reacti

60 isoproterenol (ISO), phenylephrine (PE), and endothelin-1 (ET-1).

61 In EOC, the endothelin-1 (ET-1, EDN1)-endothelin A receptor (ETAR, E

62 Endothelin-1 (ET1) synthesis is understood to promote ca

63 ubgroup with pulmonary hypertension and high endothelin-1 (high endothelin-1: >/=1.7 pg/mL; upper qua

64 lin-1; and no pulmonary hypertension and low endothelin-1 (log-rank chi2 = 77.16; P < .01 ).

65 these proteins in DN, and demonstrated that endothelin-1 activates podocytes to release heparanase.

66 Endothelin-1 activates the phospholipase C pathway, lead

67 of ARHGAP18 resulted in a failure to secrete endothelin-1 and a reduction in neutrophil transmigratio

68 r basal conditions and after the addition of endothelin-1 and abnormal spontaneous Ca(2+) release eve

69 (OPN) in mouse arteries via local release of endothelin-1 and activation of CREB.

70 y PGP levels associate with both circulating endothelin-1 and acute rejection in cardiac transplant p

71 eraction with GRK2 is inversely regulated by endothelin-1 and CAV1 scaffolding domain after liver inj

72 lacylcarnitines correlated with increases in endothelin-1 and creatinine/cystatin C, respectively.

73 Epithelial-derived endothelin-1 and fibroblast growth factor were also augm

74 -beta1 signaling and increased expression of endothelin-1 and genes involved in VSMC contraction, hig

75 However, endothelin-1 and IL-6 increased, and IL-10 decreased, be

76 Levels of endothelin-1 and markers of fibrinolysis and inflammatio

77 Plasma endothelin-1 and OPN concentrations are positively corre

78 Despite pathophysiological links between endothelin-1 and pulmonary vascular remodeling, to our k

79 e previously showed that both heparanase and endothelin-1 are essential for the development of DN.

80 es of evidence have demonstrated the role of endothelin-1 as both a constrictor of uterine myometrial

81 tor-2, and the potent vasoconstrictive agent endothelin-1 as compared with control cells.

82 In injured SECs, endothelin-1 blocked CAV1 phosphorylation induced by CAV

83 y in systemic sclerosis after macitentan, an endothelin-1 blocker.

84 emokine Receptor 2 (CXCR2) and production of endothelin-1 both in vitro and in vivo.

85 a) and the neuroendocrine regulatory peptide endothelin-1 by DH82 cells.

86 Also, whether endothelin-1 can predict future heart failure and mortal

87 This evidence suggests that endothelin-1 drives development of glomerulosclerosis an

88 Stimulation of primary mouse podocytes with endothelin-1 elicited rapid calcium transients mediated

89 Mediation analysis showed that BNP and endothelin-1 explained 56% and 40%, respectively, of the

90 pain behavior, epidermal tissue damage, and endothelin-1 expression.

91 ivation and angiotensin-induced increases in endothelin-1 expression.

92 fibroblasts were treated with 20 and 100 nM endothelin-1 for 6 and 24 hours and then collected to as

93 en a modest ( approximately 35%) decrease in endothelin-1 gene (Edn1) expression is sufficient to cau

94 dney vasculature and normalized Tgf-beta and endothelin-1 gene expression in aged MWF rats.

95 array analysis showed increased Tgf-beta and endothelin-1 gene expression with age.

96 generated low-expressing and high-expressing endothelin-1 genes (L and H) and have bred mice with fou

97 phy signaling triggered by angiotensin II or endothelin-1 in HEK293T cells as well as in neonatal and

98 the expression of contractile markers and of endothelin-1 in VSMCs.

99 In vitro, treatment with endothelin-1 increased total beta-catenin and phospho-NF

100 s not known whether elevated serum levels of endothelin-1 indicate future risk of kidney disease in t

101 We conclude that endothelin-1 is critical for maintaining normal contract

102 0.05), but not in vascular endothelial cell endothelin-1 knockout (VEET KO) mice (76.4 +/- 5.7 pg/mg

103 ular risk in black adults, we measured serum endothelin-1 level at baseline (2000-2004; n=3538).

104 Phenotyping by pulmonary hypertension and endothelin-1 level showed mortality decreasing in order

105 Log-transformed plasma endothelin-1 level.

106 ur knowledge, the association between plasma endothelin-1 levels and pulmonary hypertension has not b

107 ied African American individuals with plasma endothelin-1 levels and tricuspid regurgitation on echoc

108 In conclusion, higher baseline serum endothelin-1 levels associated with incident CKD and all

109 en-binding activity, soluble E-selectin, and endothelin-1 levels by using ELISA and BRAHMS Kryptor te

110 Participants with baseline endothelin-1 levels in higher quartiles had a greater in

111 Mean (SD) endothelin-1 levels were 1.36 (0.64) pg/mL; 217 of 3223

112 g for potential confounders, log-transformed endothelin-1 levels were associated with increased odds

113 Log-transformed endothelin-1 levels were associated with mortality (adju

114 Basal and angiotensin-stimulated big endothelin-1 levels were elevated in Tg(Prkcb)apoE-/- mi

115 terminal telopeptide of collagen type I, and endothelin-1 levels were higher in diabetic patients (p

116 Endothelin-1 levels were significantly increased 20 hr a

117 Elevated plasma endothelin-1 levels, especially associated with an eleva

118 tion of the endothelin-A receptor (EDNRA) by endothelin-1 may play a role in the disease because the

119 However, no direct pathogenic effect of endothelin-1 on podocytes has been shown in vivo and end

120 hese results indicate that activation of the endothelin-1 pathways selectively in podocytes mediates

121 Endothelin-1 positively associated with all-cause mortal

122 Endothelin-1 promotes mesangial cell proliferation and s

123 Endothelin-1 promotes vasculopathy in systemic sclerosis

124 Our data do not support the use of the dual endothelin-1 receptor antagonist, bosentan, in patients

125 Treatment with endothelin-1 receptor antagonists could theoretically im

126 , whereas pretreatment of rats with the dual endothelin-1 receptor blocker, bosentan, improved cell e

127 ion was associated with increased glomerular endothelin-1 receptor type A (Ednra) expression and incr

128 physiologically important thromboxane A2 and endothelin-1 receptors.

129 Of these, the vasoconstrictive factor endothelin-1 serves as an integral point of communicatio

130 in-1 on podocytes has been shown in vivo and endothelin-1 signaling in podocytes has not been investi

131 Our data suggest that in diabetes, endothelin-1 signaling, as occurs in endothelial activat

132 Endothelin-1 stimulated the production of MMP1, MMP8, an

133 These pathways were activated by endothelin-1 through the ETB receptor; inhibiting recept

134 anti-angiotensin II type-1 receptor and anti-endothelin-1 type A receptor autoantibodies are associat

135 tatus for angiotensin II type-1 receptor and endothelin-1 type A receptor autoantibodies pre-LT, and

136 The extracellular concentration of endothelin-1 was increased following GLO1-knockdown, whe

137 Moreover, Ca(2+) release stimulated by endothelin-1 was inhibited by Ned-19, ryanodine, or xest

138 the effect of IRL-1620 [Suc-[Glu9,Ala11,15]-Endothelin-1(8-12)] on astrocytes, neurons, and vascular

139 ious pruritogens (histamine, chloroquine, or endothelin-1) and recorded spontaneous scratching before

140 ddressing 1 abnormality (eg, upregulation of endothelin-1) and were not developed specifically for PA

141 en-binding activity, soluble E-selectin, and endothelin-1) were significantly increased during HAE at

142 to histaminergic (histamine, compound 48/80, endothelin-1), not non-histaminergic (chloroquine) pruri

143 creased production of vasoconstrictors (e.g. endothelin-1).

144 ure to vasoconstrictors (50 mM KCl and 20 nM Endothelin-1).

145 (adjusted hazard ratio per log increment in endothelin-1, 1.57, 95% CI, 1.05-2.37; median follow-up,

146 on (adjusted odds ratio per log increment in endothelin-1, 1.66; 95% CI, 1.16-2.37).

147 (adjusted hazard ratio per log increment in endothelin-1, 1.69; 95% CI, 1.27-2.25; median follow-up,

148 Endothelin-1, a marker of endothelial dysfunction, is a

149 Endothelin-1, a potent vasoconstrictor, plays an importa

150 is determined by venous endothelium-derived endothelin-1, acting through its specific receptor Ednra

151 activation, such as smooth muscle actin and Endothelin-1, and all of these genes play a key role in

152 (ICAM-1), anti-LG3, aminopeptidase N, CXCL9, endothelin-1, and gelsolin.

153 transforming growth factor beta1 (TGFbeta1), endothelin-1, and NAD(P)H oxidase 4 also occur in parall

154 k involving transforming growth factor-beta, endothelin-1, angiotensin II, CCN2 (connective tissue gr

155 procalcitonin, MR-pro-adrenomedullin, CT-pro-endothelin-1, CT-pro-arginine vasopressin, and MR-pro-at

156 such as transforming growth factor beta1 and endothelin-1, enhance RBC NADPH oxidase activity and inc

157 tes production of the potent vasoconstrictor endothelin-1, producing pulmonary hypertension.

158 l as in human disease, including the role of endothelin-1, pulmonary monocytes, and angiogenesis.

159 iewed, including nitric oxide, prostacyclin, endothelin-1, reactive oxygen species, and endothelial a

160 with elevated vasoconstrictor signalling via endothelin-1, reduces the local vasodilatory response to

161 activated gene networks involved in calcium, endothelin-1, renin-angiotensin, and cardiac beta-adrene

162 pro-B-type natriuretic peptide, aldosterone, endothelin-1, troponin I, and C-telopeptide for type I c

163 s elicited by phenylephrine, angiotensin II, endothelin-1, U46619, and K(+)-induced membrane depolari

164 n enhances epidermal expression of TRPV4 and endothelin-1, underscoring the potential of keratinocyte

165 ce has been associated with raised levels of endothelin-1, which are common both before and after Fon

166 es was increased expression and secretion of endothelin-1, which is also a known pruritogen.

167 on of vascular endothelial growth factor and endothelin-1.

168 zed mesenteric arteries pre-constricted with endothelin-1.

169 cluding BNP (B-type natriuretic peptide) and endothelin-1.

170 ary hypertension and high endothelin-1 (high endothelin-1: >/=1.7 pg/mL; upper quartile); pulmonary h

171 artiles); no pulmonary hypertension and high endothelin-1; and no pulmonary hypertension and low endo

172 a and recruitment of vasoconstrictors (e.g., endothelin-1; Edn1) leads to clearance of transplanted c

173 ased pressor responses to angiotensin II and endothelin-1; these effects are prevented by treatment w

174 ise in the expression of the vasoconstrictor endothelin 2 by follicle cells of wild-type mice.

175 e mice, infusion of vasoconstrictors (either endothelin 2 or angiotensin 2) into the bursa restored t

176 responsible for this regenerative effect of endothelin 2, analysis of both remyelination following e

177 etinae identified several cytokines (CXCL13, endothelin 2, CCL20 and CXCL2) to be significantly upreg

178 Although increasing evidence indicates that endothelin-2 (Edn2) has distinct roles in tissue patholo

179 Endothelin-2 (EDN2) is a potent vasoconstrictor that is

180 in white mutants a transcriptional defect in endothelin 3 (edn3), encoding a peptide factor that prom

181 d by molecules such as the signaling protein endothelin 3 (EDN3), its receptor (the endothelin recept

182 Mechanistically, endothelin A receptor (ETAR)-positive macrophages are hi

183 on of its cognate G protein-coupled receptor endothelin A receptor (ETAR).

184 In EOC, the endothelin-1 (ET-1, EDN1)-endothelin A receptor (ETAR, EDNRA) signaling axis regul

185 Atrasentan, a selective endothelin A receptor antagonist, has been shown to redu

186 ion of similar magnitude (P </= 0.05) of the endothelin A receptor in the lung tissue.

187 dothelin signaling via the activation of the endothelin-A receptor (EDNRA) by endothelin-1 may play a

188 Activation of endothelin-A receptor (ET(A)R) by endothelin-1 (ET-1) dr

189 o three groups: placebo (RVD+PTRAS), chronic endothelin-A receptor (ET-A) blockade (RVD+PTRAS+ET-A),

190 g-term treatment strategy with the selective endothelin-A receptor (ETA) antagonist, ambrisentan, des

191 While targeting endothelin and angiotensin, which are upstream regulator

192 factor, vascular endothelial growth factor), endothelin and inhibitors of chemotaxis.

193 increases in angiogenic mediators, including endothelins and endothelin receptor (EDNR) A.

194 tion persists in the absence of endothelium, endothelin, and cyclooxygenase mediators.

195 ion of natriuretic peptides, adrenomedullin, endothelin, and galectin-3 with new-onset HF was stronge

196 n various mediators, including nitric oxide, endothelin, and prostanoids, among others.

197 oncentration of catecholamines, vasopressin, endothelin, and renin activity in 14 patients with CIPA,

198 consisting of prostacyclin and its analogs, endothelin antagonists, phosphodiesterase-5 inhibitors,

199 Endothelins are a family of vasoactive peptides, of whic

200 Endothelins are potent vasoconstrictors and signaling mo

201 The endothelin axis and in particular the two endothelin rec

202 development of novel therapies targeting the endothelin axis.

203 The endothelin B (ETB) receptor is a G-protein-coupled recep

204 nd release of endothelin-1 (ET-1) binding to endothelin B (ETB) receptors, overexpressed in the lung

205 lular loop (IL2 or IL3, respectively) of the endothelin B receptor (ETB).

206 to a cysteine sulfenic acid modification in endothelin B receptor and consequently decreased endothe

207 BR-4628 against IR was lost when a selective endothelin B receptor antagonist was coadministered.

208 a nicotinic receptor (CHRNG, 6 subjects) and endothelin converting enzyme-like 1 (ECEL1, 4 subjects).

209 Members of the endothelin-converting enzyme (ECE) family are considered

210 nists (BQ123 plus BQ788) or by inhibition of endothelin-converting enzyme (phosphoramidon or SM19712)

211 Here, we have identified neural endothelin-converting enzyme 1 (ECE-1) as a key regulato

212 ned whether agonist degradation by endosomal endothelin-converting enzyme 1 (ECE-1) controls SSTR2A t

213 -1 expression, indicating the presence of an endothelin-converting enzyme 1/endothelin 1-SphK positiv

214 Endothelin-converting enzyme-1 (ECE-1) is the enzyme pre

215 Endothelin-converting enzyme-1 (Ece-1), a crucial compon

216 t inhibition of SphK leads to suppression of endothelin-converting enzyme-1 expression, indicating th

217 ltiplex consanguineous family to identify in endothelin-converting enzyme-like 1 (ECEL1) mutations th

218 th virulence and has a putative action as an endothelin-converting enzyme.

219 We further identify the endothelin/Ednra pathway as an autocrine activator of Gq

220 This study investigated endothelin effects in podocytes during experimental diab

221 strictive and vascular remodeling actions of endothelin (ET) 1 and angiotensin (Ang) II via endotheli

222 nd tumor necrosis factor-alpha, to stimulate endothelin (ET) and ET receptor (ETR) expression in brea

223 receptors (GPCRs), including adrenergic and endothelin (ET) receptors, after elevated neurohormonal

224 n the renin-angiotensin system (RAS) and the endothelin (ET) system as dual vasopeptidase inhibitors

225 layed a vasoconstriction response to KCl and endothelin for each experimental group.

226 osis factor-alpha, IL-1b, troponin, vascular endothelin growth factor, IL-17a, matrix metallopeptidas

227 Endothelin-induced vasoconstriction by hepatic stellate

228 C-dependent, positive-feedback mechanism for Endothelin induction and establish MEF2C as an immediate

229 est enhancer from the mouse genome abolishes Endothelin induction of Mef2c expression.

230 alyzed the expression of the complete set of endothelin ligands and receptors in the jawless vertebra

231 S/MS to identify NT-proET-1 (ppET-1[18-50]), Endothelin-Like Domain Peptide (ELDP, ppET-1[93-166]) an

232 ELDP contains the evolutionary conserved endothelin-like domain sequence, which potentially confe

233 Moreover, the results suggest that endothelin pathways have a role in the pathogenesis of M

234 iogenic mediators, including endothelins and endothelin receptor (EDNR) A.

235 y by Jagged-Notch signaling and ventrally by endothelin receptor A (EDNRA) signaling.

236 Endothelin receptor A (ETA), a G protein-coupled recepto

237 Endothelin receptor A blockade in vitro did not improve

238 angiogenesis by Edn2 requires expression of Endothelin receptor A but not Endothelin receptor B in t

239 Conditional loss of endothelin receptor A in granulosa cells also decreased

240 The endothelin receptor antagonist is among the most effecti

241 us epoprostenol were weaned off post-LT, and endothelin receptor antagonist or phosphodiesterase type

242 mendation for either prostacyclin agonist or endothelin receptor antagonist therapy and a strong reco

243 Endothelin receptor antagonists (ERA) and phosphodiester

244 s of disease-targeted therapy (predominantly endothelin receptor antagonists [47.3%] or phosphodieste

245 Endothelin receptor antagonists have emerged as a novel

246 Additionally, infusion of endothelin receptor antagonists into the bursa of wild-t

247 were receiving riociguat in combination with endothelin receptor antagonists or prostanoids, or both.

248 erent classes of drugs are now available-ie, endothelin receptor antagonists, phosphodiesterase-5 inh

249 se biological effects that are unaffected by endothelin receptor antagonists.

250 We observed that endothelin receptor B [ET-B (gene name EDNRB)], the rece

251 expression of Endothelin receptor A but not Endothelin receptor B in the neural retina.

252 ts may constitute the mechanism of action of endothelin receptor blockers in DN.

253 In mice, podocyte-specific knockout of the endothelin receptor prevented the diabetes-induced incre

254 The endothelin receptor type A (EDNRA) signaling pathway is

255 dothelin (ET) 1 and angiotensin (Ang) II via endothelin receptor type A (ETAR) and Ang receptor type-

256 These cells highly expressed endothelin receptor type B (ETB(R)) and Jagged1, a Notch

257 otein endothelin 3 (EDN3), its receptor (the endothelin receptor type B [EDNRB]), and the transcripti

258 Antagonists of endothelin receptor type B also inhibited remyelination

259 n post-mortem tissue revealed high levels of endothelin receptor type B in oligodendrocyte lineage ce

260 genome sequencing, we discovered that EDNRB (Endothelin receptor type B) is a candidate gene involved

261 development and suggest that modification of endothelin receptor-ligand specificity was a key step in

262 essed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end poin

263 Endothelin-receptor antagonists are in clinical use to t

264 hypertension and patients who were receiving endothelin-receptor antagonists or (nonintravenous) pros

265 the disease and in those who were receiving endothelin-receptor antagonists or prostanoids.

266 c receptors, alpha-adrenergic receptors, and endothelin receptors (among others) have been associated

267 d podocyte loss through direct activation of endothelin receptors and NF-kappaB and beta-catenin path

268 Endothelin receptors are also expressed on the human ecc

269 ednra and ednrb, the genes encoding the two Endothelin receptors in mice, were born at predicted Men

270 he endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for thera

271 We show that Endothelin signaling activates Mef2c expression in the n

272 Moreover, we demonstrate that Endothelin signaling activates neural crest expression o

273 These data suggest that OA-NO2 modulates endothelin signaling by increasing Nrf2-dependent expres

274 duplication and specialization of vertebrate Endothelin signaling coincided with the appearance of hi

275 ednr expression, we also analyzed all known Endothelin signaling components in the African clawed fr

276 To test the potential role of endothelin signaling diversification in the evolution of

277 nscriptional effectors directly activated by Endothelin signaling during neural crest development rem

278 he cardiac conduction system in mice lacking Endothelin signaling has not been previously addressed.

279 amine in more detail the effect of OA-NO2 on endothelin signaling in human endothelial cells.

280 However, the role of Endothelin signaling in mammalian conduction system deve

281 tream transcriptional target and effector of Endothelin signaling in the neural crest.

282 diate transcriptional effector and target of Endothelin signaling in the neural crest.

283 In jawed vertebrates, Endothelin signaling involves multiple functionally dist

284 r neural crest development, and dysregulated Endothelin signaling is associated with several neural c

285 thin the developing mammalian heart and that Endothelin signaling is dispensable for specification an

286 Endothelin signaling is essential for neural crest devel

287 Endothelin signaling is required for neural crest migrat

288 primarily on gain-of-function studies, that Endothelin signaling is responsible for myocyte-to-Purki

289 enzyme-1 (Ece-1), a crucial component of the Endothelin signaling pathway, is required for embryonic

290 Endothelin signaling regulates several aspects of NCC de

291 Endothelin signaling via the activation of the endotheli

292 ETA), a G protein-coupled receptor, mediates endothelin signaling, which is regulated by GRK2.

293 nduction system in mouse embryos lacking all Endothelin signaling.

294 The endothelin system has emerged as a novel target for the

295 We hypothesized that activation of the endothelin system via EDNRA plays a causal role in patho

296 FRET-based biosensors, we show that LPA and endothelin transiently activate Cdc42 through Gi, concur

297 es to angiotensin type 1 receptor (AT1R) and endothelin type A receptor (ETAR) is associated with all

298 s significantly increased by blockade of the endothelin type A receptor with ABT-627 (0.116 +/- 0.006

299 licited rapid calcium transients mediated by endothelin type A receptors (ETARs) and endothelin type

300 d by endothelin type A receptors (ETARs) and endothelin type B receptors (ETBRs).